

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 March 2019 (14.03.2019)



(10) International Publication Number
WO 2019/050478 A1

(51) **International Patent Classification:**
C12Q 1/6886 (2018.01) *G01N 33/574* (2006.01)

(21) **International Application Number:**
PCT/SG2018/050450

(22) **International Filing Date:**
05 September 2018 (05.09.2018)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**
10201707218R 05 September 2017 (05.09.2017) SG

(71) **Applicants: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). **SINGAPORE HEALTH SERVICES PTE. LTD.** [SG/SG]; 31 Third Hospital Avenue., #03-03, Bowyer Block C, Singapore 168753 (SG).

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(72) **Inventors: YAO, Xiaosai**; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore 138672 (SG). **TAN, Patrick**; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore 138672 (SG). **TEH, Bin Tean**; c/o National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610 (SG). **TAN, Jing**; c/o National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610 (SG). **SHAO, Huilin**; c/o Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, Singapore 138673 (SG). **KOH, Joanna**; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore 138672 (SG).

(74) **Agent: SPRUSON & FERGUSON (ASIA) PTE LTD**; P.O. Box 1531, Robinson Road Post Office, Singapore 903031 (SG).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(54) **Title: CLEAR CELL RENAL CELL CARCINOMA BIOMARKERS**

(57) **Abstract:** Disclosed herein is a clear cell renal cell carcinoma (ccRCC) biomarker comprising at least 2 biomarkers selected from the group consisting of ZNF395, SMPDL3A, SLC28A1, SLC6A3, VEGFA, EGLN3, wherein at least one of the two biomarkers is SMPDL3A or SLC28A1. Also enclosed herein is a detection system using the biomarker set disclosed herein, methods of determining whether a subject has or shows recurrence of clear cell renal cell carcinoma, methods of determining whether a renal mass sample is benign or malignant, method of detecting response of a subject to systemic treatment, and a kit for carrying out the same.



WO 2019/050478 A1